Although FXR, HIF2a, and MYC alter ceramide formation through unique processes, each system promotes the delivery of ceramides from the intestine to other tissues, including the liver, thereby impairing systemic metabolic integrity in obesity. The gene discussed is NR1H4; the disease is obesity disorder.